Myeloproliferative Neoplasms (MPN)

Kirk R. Schultz, MD

Institution
British Columbia Children’s Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Pediatric
About
Dr. Kirk Schultz is a Professor at the University of British Columbia, BC Children’s Hospital, and the Child and Family research Institute (CFRI) who has published over 130 peer-reviewed articles in scientific journals. He is a Pediatric Hematologist/Oncologist focused on new therapies and rejection in Blood and Marrow Transplantation (BMT) and immune therapy of blood cancers.Dr. Schultz was the recipient of the CIHR/Wyeth Clinical Research Chair in Transplantation and is past chair of the Pediatric BMT Consortium the largest children’s BMT clinical trials group in the world. He was recently

Daria Babushok, MD, PhD

Institution
Hospital of the University of Pennsylvania
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Daria Babushok’s research is focused on understanding the genetic changes that can arise in the bone marrow of patients with aplastic anemia, and on how they affect the patients’ prognosis and treatment outcomes. Dr. Babushok has completed a clinical hematology-oncology fellowship at the Hospital of the University of Pennsylvania, and is currently a junior physician-scientist investigator at the University of Pennsylvania under the mentorship of Dr. Monica Bessler. In a study recently published in the journal of Cancer Genetics and conducted with the support of the AA&MDS International

Blood Transfusion Safety and Risks

Negative side effects of blood transfusion therapy are uncommon. Blood banks, hospitals, and health-care providers take many precautions to minimize risks before each blood transfusion.

Blood banks test each unit of blood to find out its ABO type and Rh status. In the United States, after a hospital laboratory receives a blood unit from the blood bank, the laboratory tests the unit again.

 

Guillermo Garcia-Manero, MD

Institution
Department of Leukemia at MD Anderson Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
My main academic and clinical objective is to, if not cure, at least contribute to significantly better outcomes for patients with Myelodysplastic Syndromes (MDS). I am the Chief of the Section of MDS in the Department of Leukemia at MD Anderson Cancer Center. I have built this into the largest clinical program of its class. One hundred percent of my research and clinical effort is devoted to patients with MDS.

Christopher Cogle, MD

Institution
University of Florida Health Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Cogle is an associate professor of medicine at the University of Florida, Gainesville. He has clinical and research expertise in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and allogeneic hematopoietic cell transplant. Dr. Cogle leads a research laboratory that studies the biology of MDS and AML, and his group has successfully translated his discoveries into new treatments for patients. Dr. Cogle’s goal is to fi nd cures for MDS and leukemia, educate patients and providers about the distinct heterogeneity of these diseases, educate policy makers that blood cancers are a

Olatoyosi Odenike, MD

Institution
University of Chicago Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Odenike is Professor of Medicine and Director of the Leukemia Program at the University of Chicago. Her clinical interests are in acute and chronic leukemias, myeloproliferative neoplasms, myelodysplastic syndromes, and stem cell transplantation. Her research is focused on the development of novel therapeutic agents for the treatment of acute and chronic leukemias, and chronic myeloproliferative diseases, with the ultimate goal of improving treatment options for patients with these diseases. She is the principal investigator on a number of clinical trials investigating molecularly targeted

Gail J. Roboz, M.D.

Institution
New York Presbyterian Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Gail J. Roboz, M.D. is a professor of medicine and Director of the Clinical and Translational Leukemia Programs at the Weill Medical College of Cornell University and the NewYork Presbyterian Hospital in New York City. Dr. Roboz graduated summa cum laude from Yale University and received her medical degree from The Mount Sinai School of Medicine in New York, where she was elected to the Alpha Omega Alpha Honor Medical Society and achieved the highest academic standing in the graduating class. She completed her internship in internal medicine at The Beth Israel Hospital in Boston and a
Subscribe to Myeloproliferative Neoplasms (MPN)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.